254 related articles for article (PubMed ID: 21450183)
21. Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women.
Goode PS; Burgio KL; Locher JL; Umlauf MG; Lloyd LK; Roth DL
J Am Geriatr Soc; 2002 May; 50(5):808-16. PubMed ID: 12028165
[TBL] [Abstract][Full Text] [Related]
22. Optimum Dose of Once-Daily Oxybutynin Patch in Japanese Patients with Overactive Bladder: A Randomized Double-Blind Trial Versus Placebo.
Yamaguchi O; Uchida E; Higo N; Minami H; Kobayashi S; Sato H;
Low Urin Tract Symptoms; 2016 Sep; 8(3):150-8. PubMed ID: 27619779
[TBL] [Abstract][Full Text] [Related]
23. Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial.
Wang AC; Chih SY; Chen MC
Urology; 2006 Nov; 68(5):999-1004. PubMed ID: 17113893
[TBL] [Abstract][Full Text] [Related]
24. Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships.
Gupta SK; Sathyan G; Lindemulder EA; Ho PL; Sheiner LB; Aarons L
Clin Pharmacol Ther; 1999 Jun; 65(6):672-84. PubMed ID: 10391673
[TBL] [Abstract][Full Text] [Related]
25. Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials.
Nijman RJ; Borgstein NG; Ellsworth P; Djurhuus JC
J Urol; 2005 Apr; 173(4):1334-9. PubMed ID: 15758796
[TBL] [Abstract][Full Text] [Related]
26. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
27. [Oxybutynin-Kentera].
Duh D; Vandevijver A
J Pharm Belg; 2007; 62(3):99-100. PubMed ID: 17955962
[No Abstract] [Full Text] [Related]
28. [Assessment of effectiveness of and tolerance to oxybutynin in the treatment of unstable bladder in women].
Serrano Brambila EA; Quiroga Avila RG; Lorenzo Monterrubio JL; Moreno Aranda J
Ginecol Obstet Mex; 2000 Apr; 68():174-81. PubMed ID: 10824450
[TBL] [Abstract][Full Text] [Related]
29. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study.
Wagg A; Dale M; Tretter R; Stow B; Compion G
Eur Urol; 2013 Jul; 64(1):74-81. PubMed ID: 23332882
[TBL] [Abstract][Full Text] [Related]
30. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
Malone-Lee JG; Al-Buheissi S
BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome.
Sand PK; Davila GW; Lucente VR; Thomas H; Caramelli KE; Hoel G
Am J Obstet Gynecol; 2012 Feb; 206(2):168.e1-6. PubMed ID: 21963104
[TBL] [Abstract][Full Text] [Related]
32. Multi-center randomized controlled trial of cognitive treatment, placebo, oxybutynin, bladder training, and pelvic floor training in children with functional urinary incontinence.
van Gool JD; de Jong TP; Winkler-Seinstra P; Tamminen-Möbius T; Lax H; Hirche H; Nijman RJ; Hjälmås K; Jodal U; Bachmann H; Hoebeke P; Walle JV; Misselwitz J; John U; Bael A;
Neurourol Urodyn; 2014 Jun; 33(5):482-7. PubMed ID: 23775924
[TBL] [Abstract][Full Text] [Related]
33. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence.
Madersbacher H; Halaska M; Voigt R; Alloussi S; Höfner K
BJU Int; 1999 Oct; 84(6):646-51. PubMed ID: 10510109
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: A randomized double-blind trial.
Yamaguchi O; Uchida E; Higo N; Minami H; Kobayashi S; Sato H;
Int J Urol; 2014 Jun; 21(6):586-93. PubMed ID: 24350662
[TBL] [Abstract][Full Text] [Related]
35. A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth.
Corcos J; Casey R; Patrick A; Andreou C; Miceli PC; Reiz JL; Harsanyi Z; Darke AC;
BJU Int; 2006 Mar; 97(3):520-7. PubMed ID: 16469019
[TBL] [Abstract][Full Text] [Related]
36. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
[TBL] [Abstract][Full Text] [Related]
37. Rehabilitation vs drug therapy for urge urinary incontinence: short-term outcome.
Kafri R; Langer R; Dvir Z; Katz-Leurer M
Int Urogynecol J Pelvic Floor Dysfunct; 2007 Apr; 18(4):407-11. PubMed ID: 16832589
[TBL] [Abstract][Full Text] [Related]
38. An evaluation of patient and physician satisfaction with controlled-release oxybutynin 15 mg as a one-step daily dose in elderly and non-elderly patients with overactive bladder: results of the STOP study.
Aaron LE; Morris TJ; Jahshan P; Reiz JL
Curr Med Res Opin; 2012 Aug; 28(8):1369-79. PubMed ID: 22769237
[TBL] [Abstract][Full Text] [Related]
39. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
40. Is drug therapy for urinary incontinence used optimally in long-term care facilities?
Narayanan S; Cerulli A; Kahler KH; Ouslander JG
J Am Med Dir Assoc; 2007 Feb; 8(2):98-104. PubMed ID: 17289539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
